Literature DB >> 15470193

Failing the public health--rofecoxib, Merck, and the FDA.

Eric J Topol1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15470193     DOI: 10.1056/NEJMp048286

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  115 in total

1.  Translational research: current status, challenges and future strategies.

Authors:  Dale Yu
Journal:  Am J Transl Res       Date:  2011-09-12       Impact factor: 4.060

2.  The value of observational cohort studies for cancer drugs.

Authors:  David R Spigel
Journal:  Biotechnol Healthc       Date:  2010

Review 3.  Cellular reprogramming: a new technology frontier in pharmaceutical research.

Authors:  Amy Brock; Hui-Tong Goh; Binxia Yang; Yu Lu; Hu Li; Yuin-Han Loh
Journal:  Pharm Res       Date:  2011-11-09       Impact factor: 4.200

4.  Drug research: marketing before evidence, sales before safety.

Authors:  David Klemperer
Journal:  Dtsch Arztebl Int       Date:  2010-04-23       Impact factor: 5.594

5.  Individualizing drug therapy, and 'men behaving badly'.

Authors:  E J Begg
Journal:  Br J Clin Pharmacol       Date:  2004-11       Impact factor: 4.335

6.  Drug safety on trial. Last year's withdrawal of the anti-arthritis drug Vioxx triggered a debate about how to better monitor drug safety even after approval.

Authors:  Mark Greener
Journal:  EMBO Rep       Date:  2005-03       Impact factor: 8.807

7.  Clinical trials report. The APPROVe study: what we should learn from the VIOXX withdrawal.

Authors:  Frank T Ruschitzka
Journal:  Curr Hypertens Rep       Date:  2005-02       Impact factor: 5.369

8.  Lessons to be learned from the Vioxx debacle.

Authors:  George A Beller
Journal:  J Nucl Cardiol       Date:  2005 Jan-Feb       Impact factor: 5.952

9.  Regulating the drugs industry transparently.

Authors:  John Abraham
Journal:  BMJ       Date:  2005-09-10

Review 10.  The precautionary principle and pharmaceutical risk management.

Authors:  Torbjörn Callréus
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.